Vandétanib, modalités pratiques d’utilisation dans le traitement des patients atteints de cancer médullaire de la thyroïde
- 1 September 2014
- journal article
- review article
- Published by Elsevier in Bulletin du Cancer
- Vol. 101 (9) , 891-895
Abstract
Medullary thyroid cancer (MTC) is a rare cancer. Vandetanib, a RET tyrosine-kinase inhibitor, significantly increased progression free survival and is the first treatment approved in France for unresectable, locally advanced or metastatic MTC that is symptomatic or progressive. Most frequents adverse events are diarrhea, folliculitis and asthenia. The prolongation of the QT interval on electrocardiogram is frequent but in the most of cases not clinically relevant. A good selection of the patients who could benefit from this treatment and management of side effect are important for the risk-benefit assessment.Keywords
This publication has 16 references indexed in Scilit:
- SomaticRASMutations Occur in a Large Proportion of SporadicRET-Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified ExonThe Journal of Clinical Endocrinology & Metabolism, 2012
- Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling TimeJournal of Clinical Oncology, 2012
- Medullary Thyroid CarcinomaClinical Oncology, 2010
- Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2010
- Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerJournal of Clinical Oncology, 2010
- Medullary Thyroid Cancer: Management Guidelines of the American Thyroid AssociationThyroid®, 2009
- Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future DirectionsThe Oncologist, 2009
- Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted RadioimmunotherapyThe Journal of Clinical Endocrinology & Metabolism, 2007
- Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin LevelsThe Journal of Clinical Endocrinology & Metabolism, 2007
- Prognosis of medullary thyroid carcinomaCancer, 2006